BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DASCS - ECPv4.9.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DASCS
X-ORIGINAL-URL:http://dascs.dk
X-WR-CALDESC:Events for DASCS
BEGIN:VTIMEZONE
TZID:"Europe/Copenhagen"
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20140330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20141026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID="Europe/Copenhagen":20140303T083000
DTEND;TZID="Europe/Copenhagen":20140303T153000
DTSTAMP:20260827T005034
CREATED:20140220T074844Z
LAST-MODIFIED:20140220T074844Z
UID:723-1393835400-1393860600@dascs.dk
SUMMARY:SCOTTISH STEM CELL & REGENERATIVE MEDICINE SEMINAR
DESCRIPTION:Medicon Valley Alliance in cooperation with Scottish Development International (SDI) are delighted to welcome you to participate in an exclusive seminar and partnering meeting\, gathering the best of Scotland’s stem cell and regenerative medicine industry. \nThis high-level seminar and partnering meeting\, will showcase key speakers from Scotland’s dynamic regenerative medicine community giving you the opportunity to see why it’s one of Europe’s leading stem cell hubs. \nFollowing the morning’s speakers\, Scottish and Nordic biotechnology companies will participate in a networking lunch with a further opportunity for dedicated one-to-one meetings with Scottish companies in the afternoon. This seminar is an ideal and unique chance to network and establish new contacts at a senior and specialised level between Scotland and the Nordics. \nThe seminar is open to biotech and pharma companies and investors within the life science industry. \n\nSIGN UP \nProgram \n08.30-09.00   Registration: coffee/tea/croissant \n09.00-09.10   SDI: Welcome to Scottish Stem Cell & Regenerative Medicine Seminar \n09.10-09.30   Sistemic: The role of improved product characterization on the development and approval of cell therapy products \n09.30-09.50   Clyde Bioscience: Preclinical cardiac safety testing – stem cell quality control and characterisation \n09.50-10.10   Roslin Cells: Manufacturing best practice to ensure quality control\, regulatory compliance and commercial success \n10.10-10.20   Horizon 2020: Opportunities for funding through consortia in Regenerative Medicine \n10.20-10.40   Break & Networking \n10.40-11.00   TC Biopharm: Clinical and commercial success of developing cell-derived immunotherapies in Scotland \n11.00-11.20   John Casey: Pancreatic islet transplantation for Type 1 Diabetes \n11.20-11.40   Will Shu: 3D cell printing \n11.40-12.00   BioGelX: Viable 3D cell culture: tuneable and functional peptide gels \n12.00-12.05   SDI: Closing remarks \n12.05-13.30   Networking & Lunch \n13.30-15.30   One-to-One Partnering: Pre-arranged one-to-one partnering meetings. If you are interested in taking part\, please email Adam Murray (adam.murray@scotent.co.uk). \nThe following Scottish companies and academics will be attending this meeting: \n\n\n\n\nBioGelX – David Lightbody (CEO): Develops and supplies tuneable and functional peptide gels for use as tissue mimics for specific cell type environments.\nRoslin Cells – Aidan Courtney (CEO): Specialist services for the development and manufacture of new cell therapies and stem cell research using world leading isolation of new clinical grade pluripotent and multipotent stem cells.\nSistemic – Daria Olijnyk (Senior Staff Scientist): Specialist contract research\, discovery and development services based on a proprietary position around micro RNAs allowing stem cell identification\, process characterisation and directed differentiation.\nTC Biopharm – Mike Leek (CEO): Start-up biotechnology company developing a novel anti-cancer immunotherapy using patients’ own immune cells for the treatment of various different types of cancer.\nClyde Biosciences – Margaret-Anne Craig (CEO): A contract research organisation supporting early stage drug development and cell line quality control and characterisation by providing accurate\, high throughput information about the effect of their proprietary Celloptiq system on ion channels.\nJohn Casey – University of Edinburgh/NHS Lothian: Consultant Transplant Surgeon at the Royal Infirmary of Edinburgh where he leads on the islet transplantation programme for Type 1 Diabetes and has helped to establish an islet isolation facility in Edinburgh.\nWill Shu – Heriot-Watt University: Reader in Microengineering within the Biomedical Microengineering Group at Heriot-Watt University in Edinburgh where he has pioneered the development of a valve-based cell printing technique that can produce viable and functional cells in a 3D system.\n\n\n\n\n\nParticipation\n\nFor members: Free of charge (late cancellation*/no-show fee DKK 500 ex VAT)\nFor non-members: Free of charge (late cancellation*/no-show fee DKK 500 ex VAT) \nRegistration ends February 26\, 2014.\n* If you cancel after the registration ends\, it is considered late cancellation. \n\n\n\n\n
URL:http://dascs.dk/?tribe_events=scottish-stem-cell-regenerative-medicine-seminar
LOCATION:MVA\, Edvard Thomsens Vej 14\, Copenhagen S\, 2300\, Denmark
END:VEVENT
END:VCALENDAR